GSK PLC closed 19.70% below its 52-week high of £16.79, which the company achieved on September 9th.

The Swedish defense company posted better-than-expected earnings and [raised its annual sales guidance]( ...

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

--In Europe, the Stoxx Europe 600 climbed 0.3% in morning trading. France's CAC 40 increased 0.4% and Germany's DAX rose 0.3%. Vestas Wind Systems added 11.6% after an upgrade. GSK lost over 6.0%, and ...

Arexvy is currently approved for use in all individuals aged 60 and older, as well as for high-risk individuals aged 50-59.

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

In the segment, while products like Nucala and Dovato are key top-line drivers, new long-acting HIV medicines, Cabenuva and ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

GSK plc (NYSE: GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA approval for a 200 mg/mL autoinjector of Benlysta (belimumab) for the ...

Senator Maggie Hassan is investigating GSK's discontinuation of Flovent HFA, citing increased hospitalizations, higher drug costs, and lost Medicaid rebates.